

Willem M Lijfering

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4616212/publications.pdf>

Version: 2024-02-01

138
papers

3,237
citations

159358

30
h-index

182168

51
g-index

138
all docs

138
docs citations

138
times ranked

4011
citing authors

#	ARTICLE	IF	CITATIONS
1	Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. <i>Blood</i> , 2009, 113, 5314-5322.	0.6	206
2	Risk factors for venous thrombosis – current understanding from an epidemiological point of view. <i>British Journal of Haematology</i> , 2010, 149, 824-833.	1.2	174
3	Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. <i>The Cochrane Library</i> , 2018, 2018, CD011054.	1.5	130
4	Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy. <i>Circulation</i> , 2019, 139, 775-786.	1.6	129
5	High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. <i>Thrombosis and Haemostasis</i> , 2009, 101, 93-99.	1.8	116
6	Risk of Recurrent Venous Thrombosis in Homozygous Carriers and Double Heterozygous Carriers of Factor V Leiden and Prothrombin G20210A. <i>Circulation</i> , 2010, 121, 1706-1712.	1.6	115
7	Sex Difference in Risk of Second but Not of First Venous Thrombosis. <i>Circulation</i> , 2014, 129, 51-56.	1.6	114
8	Differential risks in men and women for first and recurrent venous thrombosis: the role of genes and environment. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1593-1600.	1.9	103
9	Relationship between Venous and Arterial Thrombosis: A Review of the Literature from a Causal Perspective. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 885-896.	1.5	86
10	Hematologic variables and venous thrombosis: red cell distribution width and blood monocyte count are associated with an increased risk. <i>Haematologica</i> , 2014, 99, 194-200.	1.7	83
11	Skin Autofluorescence Is Associated With 5-Year Mortality and Cardiovascular Events in Patients With Peripheral Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 933-938.	1.1	78
12	Protein S levels and the risk of venous thrombosis: results from the MEGA case-control study. <i>Blood</i> , 2013, 122, 3210-3219.	0.6	73
13	Relationship between Progression to AIDS and Thrombophilic Abnormalities in HIV Infection. <i>Clinical Chemistry</i> , 2008, 54, 1226-1233.	1.5	58
14	Opioid Prescription Patterns and Risk Factors Associated With Opioid Use in the Netherlands. <i>JAMA Network Open</i> , 2019, 2, e1910223.	2.8	58
15	A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families. <i>Blood</i> , 2009, 114, 2031-2036.	0.6	54
16	The risk of venous thrombosis in individuals with a history of superficial vein thrombosis and acquired venous thrombotic risk factors. <i>Blood</i> , 2013, 122, 4264-4269.	0.6	54
17	Clinical relevance of decreased free protein S levels: results from a retrospective family cohort study involving 1143 relatives. <i>Blood</i> , 2009, 113, 1225-1230.	0.6	53
18	Increased risk of venous thrombosis in persons with clinically diagnosed superficial vein thrombosis: results from the MEGA study. <i>Blood</i> , 2011, 118, 4239-4241.	0.6	52

#	ARTICLE	IF	CITATIONS
19	Current and future burden of venous thrombosis: Not simply predictable. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 199-208.	1.0	52
20	Rosuvastatin use improves measures of coagulation in patients with venous thrombosis. European Heart Journal, 2018, 39, 1740-1747.	1.0	51
21	Risk and Risk Factors Associated With Recurrent Venous Thromboembolism Following Surgery in Patients With History of Venous Thromboembolism. JAMA Network Open, 2019, 2, e193690.	2.8	47
22	Role of Hemostatic Factors on the Risk of Venous Thrombosis in People With Impaired Kidney Function. Circulation, 2014, 129, 683-691.	1.6	46
23	Carotid Atherosclerosis Predicts Future Myocardial Infarction But Not Venous Thromboembolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 226-230.	1.1	45
24	Role of Obesity in the Etiology of Deep Vein Thrombosis and Pulmonary Embolism: Current Epidemiological Insights. Seminars in Thrombosis and Hemostasis, 2013, 39, 533-540.	1.5	44
25	Apolipoproteins A1, B, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up. Clinical Research in Cardiology, 2019, 108, 520-538.	1.5	39
26	Hyperhomocysteinemia and Risk of First Venous Thrombosis: The Influence of (Unmeasured) Confounding Factors. American Journal of Epidemiology, 2018, 187, 1392-1400.	1.6	36
27	The risk of venous and arterial thrombosis in hyperhomocysteinaemia is low and mainly depends on concomitant thrombophilic defects. Thrombosis and Haemostasis, 2007, 98, 457-463.	1.8	35
28	Lipid levels and risk of venous thrombosis: results from the MEGA-study. European Journal of Epidemiology, 2017, 32, 669-681.	2.5	35
29	Relationship between neighborhood socioeconomic status and venous thromboembolism: results from a population-based study. Journal of Thrombosis and Haemostasis, 2017, 15, 2352-2360.	1.9	33
30	Prediction of recurrent venous thrombosis in all patients with a first venous thrombotic event: The Leiden Thrombosis Recurrence Risk Prediction model (L-TRRiP). PLoS Medicine, 2019, 16, e1002883.	3.9	31
31	Hypertensive Complications of Pregnancy and Risk of Venous Thromboembolism. Hypertension, 2020, 75, 781-787.	1.3	31
32	Venous and arterial thrombosis in dialysis patients. Thrombosis and Haemostasis, 2011, 106, 1046-1052.	1.8	29
33	Statin use in patients with nephrotic syndrome is associated with a lower risk of venous thromboembolism. Thrombosis Research, 2011, 127, 395-399.	0.8	28
34	Increased risk of CVD after VT is determined by common etiologic factors. Blood, 2013, 121, 4948-4954.	0.6	28
35	Predictors, time course, and outcomes of persistence patterns in oral anticoagulation for non-valvular atrial fibrillation: a Dutch Nationwide Cohort Study. European Heart Journal, 2021, 42, 4126-4137.	1.0	28
36	Statins and Risk of Bleeding: An Analysis to Evaluate Possible Bias Due to Prevalent Users and Healthy User Aspects. American Journal of Epidemiology, 2016, 183, 930-936.	1.6	26

#	ARTICLE	IF	CITATIONS
37	Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 141-153.	1.0	26
38	Quality of life and fear of cancer recurrence in T1 colorectal cancer patients treated with endoscopic or surgical tumor resection. <i>Gastrointestinal Endoscopy</i> , 2019, 89, 533-544.	0.5	25
39	Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 319-328.	1.9	25
40	Elevated levels of factor VIII and subsequent risk of all-cause mortality: results from the MEGA follow-up study. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1833-1842.	1.9	23
41	Mild antithrombin deficiency and risk of recurrent venous thromboembolism: results from the MEGA follow-up study. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 680-688.	1.9	22
42	Different risk of deep vein thrombosis and pulmonary embolism in carriers with factor V Leiden compared with non-carriers, but not in other thrombophilic defects. Results from a large retrospective family cohort study. <i>Haematologica</i> , 2010, 95, 1030-1033.	1.7	20
43	Active cytomegalovirus infection in patients with acute venous thrombosis: A case-control study. <i>American Journal of Hematology</i> , 2011, 86, 510-512.	2.0	20
44	Interaction of Hereditary Thrombophilia and Traditional Cardiovascular Risk Factors on the Risk of Arterial Thromboembolism. <i>Circulation: Cardiovascular Genetics</i> , 2016, 9, 79-85.	5.1	20
45	Vitamin supplementation on the risk of venous thrombosis: results from the MEGA case-control study. <i>American Journal of Clinical Nutrition</i> , 2015, 101, 606-612.	2.2	19
46	Determinants of impaired renal and vascular function are associated with elevated levels of procoagulant factors in the general population. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 519-528.	1.9	19
47	Glucocorticoid use and risk of first and recurrent venous thromboembolism: self-controlled case-series and cohort study. <i>British Journal of Haematology</i> , 2021, 193, 1194-1202.	1.2	19
48	Inter- and intra-individual concentrations of direct oral anticoagulants: The KIDOAC study. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 92-103.	1.9	19
49	The risk of venous and arterial thrombosis in hyperhomocysteinemic subjects may be a result of elevated factor VIII levels. <i>Haematologica</i> , 2007, 92, 1703-1706.	1.7	18
50	Possible contribution of cytomegalovirus infection to the high risk of (recurrent) venous thrombosis after renal transplantation. <i>Thrombosis and Haemostasis</i> , 2008, 99, 127-130.	1.8	18
51	Self-reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 586-593.	1.0	18
52	Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study. <i>PLoS Medicine</i> , 2020, 17, e1003101.	3.9	18
53	Rise of levels of von Willebrand factor and factor VIII with age: Role of genetic and acquired risk factors. <i>Thrombosis Research</i> , 2021, 197, 172-178.	0.8	18
54	The relationship between DOAC levels and clinical outcomes: The measures tell the tale. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3163-3168.	1.9	17

#	ARTICLE	IF	CITATIONS
55	Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists. PLoS ONE, 2016, 11, e0164485.	1.1	16
56	Glucose metabolism affects coagulation factors: The NEO study. Journal of Thrombosis and Haemostasis, 2019, 17, 1886-1897.	1.9	16
57	<p>Association of apolipoproteins C-I, C-II, C-III and E with coagulation markers and venous thromboembolism risk</p>. Clinical Epidemiology, 2019, Volume 11, 625-633.	1.5	16
58	Causes and consequences of the opioid epidemic in the Netherlands: a population-based cohort study. Scientific Reports, 2020, 10, 15309.	1.6	16
59	Venous thromboembolism in HIV-positive women during puerperium: a case series. Blood Coagulation and Fibrinolysis, 2008, 19, 95-97.	0.5	15
60	Can we prevent venous thrombosis with statins: an epidemiologic review into mechanism and clinical utility. Expert Review of Hematology, 2016, 9, 1023-1030.	1.0	15
61	Rosuvastatin use increases plasma fibrinolytic potential: a randomised clinical trial. British Journal of Haematology, 2020, 190, 916-922.	1.2	15
62	Mesenteric vein thrombosis associated with primary cytomegalovirus infection: a case report. Blood Coagulation and Fibrinolysis, 2007, 18, 509-511.	0.5	14
63	Suspected survivor bias in case"control studies: stratify on survival time and use a negative control. Journal of Clinical Epidemiology, 2014, 67, 232-235.	2.4	14
64	Recurrent venous thrombosis related to overweight and obesity: results from the MEGA follow&sup study. Journal of Thrombosis and Haemostasis, 2017, 15, 1430-1435.	1.9	14
65	Statin Therapy to Revert Hypercoagulability and Prevent Venous Thromboembolism: A Narrative Review. Seminars in Thrombosis and Hemostasis, 2019, 45, 825-833.	1.5	13
66	Antibiotic use as a marker of acute infection and risk of first and recurrent venous thrombosis. British Journal of Haematology, 2017, 176, 961-970.	1.2	12
67	Why crowding matters in the time of COVID-19 pandemic? - a lesson from the carnival effect on the 2017/2018 influenza epidemic in the Netherlands. BMC Public Health, 2020, 20, 1516.	1.2	12
68	Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns. Journal of Thrombosis and Haemostasis, 2020, 18, 1390-1397.	1.9	12
69	The joint effect of genetic risk factors and different types of combined oral contraceptives on venous thrombosis risk. British Journal of Haematology, 2020, 191, 90-97.	1.2	12
70	Hyperhomocysteinemia is not a risk factor for venous and arterial thrombosis, and is associated with elevated factor VIII levels. Thrombosis Research, 2008, 123, 244-250.	0.8	11
71	Increased risk of arterial thromboembolism after a prior episode of venous thromboembolism: results from the Prevention of REnal and Vascular ENd stage Disease (PREVEND) Study. British Journal of Haematology, 2012, 159, 216-222.	1.2	11
72	Statin use and risk of recurrent venous thrombosis: results from the MEGA follow&sup study. Research and Practice in Thrombosis and Haemostasis, 2017, 1, 112-119.	1.0	11

#	ARTICLE	IF	CITATIONS
73	Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 689-695.	1.0	11
74	Validation of risk assessment models for venous thrombosis in hospitalized medical patients. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 217-225.	1.0	11
75	Glucose levels and diabetes are not associated with the risk of venous thrombosis: results from the <sc>MEGA</sc> case-control study. <i>British Journal of Haematology</i> , 2019, 184, 431-435.	1.2	11
76	Associations between high factor VIII and low free protein S levels with traditional arterial thrombotic risk factors and their risk on arterial thrombosis: Results from a retrospective family cohort study. <i>Thrombosis Research</i> , 2010, 126, e249-e254.	0.8	10
77	Factor V levels and risk of venous thrombosis: The MEGA case-control study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 320-326.	1.0	10
78	Multi-dose drug dispensing as a tool to improve medication adherence: A study in patients using vitamin K antagonists. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 46-51.	0.9	9
79	The risk of venous and arterial thrombosis in hyperhomocysteinaemia is low and mainly depends on concomitant thrombophilic defects. <i>Thrombosis and Haemostasis</i> , 2007, 98, 457-63.	1.8	9
80	Risk of cardiovascular disease in double heterozygous carriers and homozygous carriers of <i>F5</i> R506Q (factor V Leiden) and <i>F2</i> (prothrombin) G20210A: a retrospective family cohort study. <i>British Journal of Haematology</i> , 2011, 153, 134-136.	1.2	8
81	Bloodcurdling movies and measures of coagulation: Fear Factor crossover trial. <i>BMJ, The</i> , 2015, 351, h6367.	3.0	8
82	Direct oral anticoagulant use and risk of perioperative bleeding: Evidence of absence or absence of evidence?. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 182-185.	1.0	8
83	Differential effect of statin use on coagulation markers: an active comparative analysis in the NEO study. <i>Thrombosis Journal</i> , 2021, 19, 45.	0.9	8
84	Decreased free protein S levels and venous thrombosis in the acute setting, a case-control study. <i>Thrombosis Research</i> , 2011, 128, 501-502.	0.8	7
85	The influence of prothrombotic laboratory abnormalities on the risk of recurrent venous thrombosis. <i>Thrombosis Research</i> , 2012, 130, 974-976.	0.8	7
86	Predicting the risk of recurrent venous thrombosis: What the future might bring. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1522-1526.	1.9	7
87	Risk prediction of recurrent venous thrombosis; where are we now and what can we add?. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1527-1534.	1.9	7
88	Switching from vitamin K antagonists to direct oral anticoagulants in non-valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 339-352.	1.9	7
89	Differential risks in men and women for first and recurrent venous thrombosis: the role of genes and environment: reply. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 886-887.	1.9	6
90	Platelet reactivity in patients with venous thrombosis who use rosuvastatin: a randomized controlled clinical trial. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1404-1409.	1.9	6

#	ARTICLE	IF	CITATIONS
91	A Rapid (Differential) Effect of Rosuvastatin and Atorvastatin on High-Sensitivity Cardiac Troponin in Subjects With Stable Cardiovascular Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 311-316.	2.3	6
92	Trigger Factors for Spontaneous Intracerebral Hemorrhage: A Case-Crossover Study. <i>Stroke</i> , 2022, 53, 1692-1699.	1.0	6
93	Past provoking venous thrombosis risk situations on the risk of a recurrent thrombotic event: A cohort study. <i>Thrombosis Research</i> , 2011, 128, 227-232.	0.8	5
94	Persistence to direct oral anticoagulants for acute venous thromboembolism. <i>Thrombosis Research</i> , 2018, 167, 135-141.	0.8	5
95	The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists. <i>Thrombosis and Haemostasis</i> , 2022, 122, 377-385.	1.8	5
96	Pharmacological Prevention of Venous Thromboembolism. , 0, , 435-461.		4
97	Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1027-1036.	0.9	4
98	Risk of recurrent venous thrombosis related to past provoking risk situations. <i>Blood Coagulation and Fibrinolysis</i> , 2013, 24, 562-566.	0.5	3
99	Hyperhomocysteinaemia and the risk of recurrent venous thrombosis: results from the MEGA follow-up study. <i>British Journal of Haematology</i> , 2019, 187, 219-226.	1.2	3
100	Association Between Hepatic Triglyceride Content and Coagulation Factors. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 3004-3014.	1.1	3
101	Low absolute risk of venous and arterial thrombosis in hyperhomocysteinaemia – A prospective family cohort study in asymptomatic subjects. <i>Thrombosis and Haemostasis</i> , 2009, 101, 209-212.	1.8	3
102	Are retired physicians suitable for the coaching of clerks?. <i>International Journal of Medical Education</i> , 2017, 8, 343-350.	0.6	3
103	Stability of vitamin K antagonist anticoagulation after COVID-19 diagnosis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12597.	1.0	3
104	Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: A randomized controlled trial. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 877-887.	1.9	3
105	Link between co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system could be due to confounding. <i>BMJ, The</i> , 2014, 349, g6899-g6899.	3.0	2
106	Thromboprophylaxis after hospital discharge in acutely ill medical patients: need for trials in patients who are at high risk of venous thrombosis. <i>Journal of Thoracic Disease</i> , 2017, 9, 950-952.	0.6	2
107	Perioperative Management in Patients Using Vitamin K Antagonists: Observational Cohort Study. <i>Thrombosis and Haemostasis</i> , 2020, 120, 495-504.	1.8	2
108	Comparison of Two Different Analgesic Prescription Strategies and Healthcare Systems: Slovenia vs. the Netherlands. <i>Frontiers in Pain Research</i> , 2021, 2, 723797.	0.9	2

#	ARTICLE	IF	CITATIONS
109	The Risk of Venous Thrombosis in Different Immigrant Groups in the Netherlands. <i>Blood</i> , 2012, 120, 3393-3393.	0.6	2
110	Impact of Venous Thromboembolism on the Formation and Progression of Carotid Atherosclerosis: The TromsÅ Study. <i>TH Open</i> , 2017, 01, e66-e72.	0.7	1
111	Direct oral anticoagulant use and subsequent start of proton pump inhibitors as proxy for gastric complaints. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 1371-1378.	0.9	1
112	Nutrition and venous thrombosis: An exercise in thinking about survivor bias. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 6-8.	1.0	1
113	Reply to: Effect of statins on measures of coagulationâ€”potential role of low-density lipoprotein receptors. <i>European Heart Journal</i> , 2019, 40, 393-393.	1.0	1
114	High Soluble Thrombomodulin Is Associated with an Increased Risk of Major Bleeding during Treatment with Oral Anticoagulants: A Caseâ€”Cohort Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 070-075.	1.8	1
115	The relationship between DOAC levels and clinical outcomes: The measures tell the taleâ€”Response from original authors Lijfering et al. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1136-1138.	1.9	1
116	A Replication Study of Gene Variants Associated with Venous Thrombosis. Results From a Population-Based Nested Case-Cohort Study.. <i>Blood</i> , 2009, 114, 3985-3985.	0.6	1
117	Statin Use and Risk Of Recurrent Venous Thrombosis: Results From The MEGA Follow-Up Study. <i>Blood</i> , 2013, 122, 3623-3623.	0.6	1
118	The Risk of Venous Thrombosis Related to Increase in Body Mass Index Is Mediated by Factor VIII Induced APC-Resistance.. <i>Blood</i> , 2009, 114, 453-453.	0.6	1
119	The Risk for Venous Thrombosis in Patients with Increased Body Mass Index and Interactions with Other Genetic and Acquired Risk Factors: The MEGA Study. <i>Blood</i> , 2011, 118, 1234-1234.	0.6	1
120	The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists. <i>Blood</i> , 2021, 138, 1066-1066.	0.6	1
121	Effect of lowerâ€”leg trauma and knee arthroscopy on procoagulant phospholipidâ€”dependent activity. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12729.	1.0	1
122	Determinants of impaired renal and vascular function are associated with elevated levels of procoagulant factors in the general population: reply. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2535-2536.	1.9	0
123	Role of Routine Laboratory Tests in Assessing Risk of Recurrent Venous Thrombosis: Results from the MEGA Follow-Up Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1918-1929.	1.8	0
124	Risk of recurrent venous thromboembolism related to prior risk situations: re-evaluation of a cohort study with a longer follow-up. <i>Blood Coagulation and Fibrinolysis</i> , 2020, 31, 434-439.	0.5	0
125	Statins in venous thrombosis: biochemical approaches to limiting vascular disease. , 2021, , 249-254.		0
126	No Difference in Risk of Recurrent Venous Thrombosis between Men and Women. Results from a Family Cohort Study in 3356 Subjects.. <i>Blood</i> , 2007, 110, 130-130.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Free Protein S Levels on the Risk of First Venous Thrombosis and Recurrence. Results from a Retrospective Family Cohort Study in 1143 Relatives.. Blood, 2008, 112, 1808-1808.	0.6	0
128	Associations Between Free Protein S and Factor VIII Levels with Traditional Arterial Thrombotic Risk Factors and Their Risk On Arterial Thrombosis. Results From a Retrospective Family Cohort Study.. Blood, 2009, 114, 25-25.	0.6	0
129	Free and Total Protein S Antigen Levels on the Risk of Venous Thrombosis: Results From the MEGA Study. Blood, 2011, 118, 538-538.	0.6	0
130	The Association Between Atherosclerosis and Venous Thrombosis: Results From the TromsÅ, Study.. Blood, 2012, 120, 2245-2245.	0.6	0
131	Risk of Venous Thrombosis Associated with White Cell Count On Peripheral Blood and Its Interrelationship with Other Environmental Risk Factors. Blood, 2012, 120, 1149-1149.	0.6	0
132	Association of Risk of Incident and Recurrent Venous Thromboembolism with Oral Glucocorticoid Treatment. Blood, 2018, 132, 420-420.	0.6	0
133	Risk of drug-related upper gastrointestinal bleeding in the total population of the Netherlands: a time-trend analysis. BMJ Open Gastroenterology, 2022, 9, e000733.	1.1	0
134	Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study. , 2020, 17, e1003101.		0
135	Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study. , 2020, 17, e1003101.		0
136	Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study. , 2020, 17, e1003101.		0
137	Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study. , 2020, 17, e1003101.		0
138	â€œEffect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolismâ€ Comment. Journal of Thrombosis and Haemostasis, 2022, 20, 1747-1747.	1.9	0